Fungal pathogenicity emerging through functional adaptations to host environments
The status, timeline and source of this project. A free account opens every field.
Source: EU Funding & Tenders Portal
Fungal infections pose a serious medical threat, especially when they invade the bloodstream. The most common cause of fungal bloodstream infections is invasive candidemia, primarily attributed to a small group of pathogens, including Candida albicans, Nakaseomyces glabratus, Candida tropicalis, and Candida parapsilosis. Such infections are associated with crude mortality rates nearing 40%. Increa
- Status
- Prospective
- Sector
- Hospital
- Location
- Germany
- Updated
- 19 Nov 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Fungal pathogenicity emerging through functional adaptations to host environments
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | forthcoming |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | Fungal infections pose a serious medical threat, especially when they invade the bloodstream. The most common cause of fungal bloodstream infections is invasive candidemia, primarily attributed to a small group of pathogens, including Candida albicans, Nakaseomyces glabratus, Candida tropicalis, and Candida parapsilosis. Such infections are associated with crude mortality rates nearing 40%. Increasing numbers of very closely related yet non-pathogenic species have been sequenced and identified. However, a functional understanding of what differentiates them from their pathogenic counterparts is lacking. As fungal pathogenicity is a multifactorial trait that is influenced by intrinsic and extrinsic factors, it is hard to explain directly from genomic data. This proposal aims to address these challenges by integrating molecular data with physiological contexts across a broad set of species with varying pathogenicity. By leveraging recent advances in mass spectrometry-based analytics that allow for large-scale molecular profiling of both microbial pathogens and human biofluids, combined with high-throughput methods for deep phenotyping of microbial isolates, and by using and identifying scalable yet physiologically relevant growth conditions and infection-relevant phenotypes, we aim to (1) identify adaptations required for pathogenicity and their molecular basis; (2) identify infection-relevant phenotypes and metabolic differences that distinguish pathogenic from non-pathogenic species; and (3) obtain a quantitative understanding of host-pathogen physiology and their interactions. Thus, we aim to uncover traits, phenotypes, and conditions that enable and intersect with pathogenicity. These breakthroughs will be critical for managing and combating these life-threatening infections and predicting the future emergence of human fungal pathogens. |
Location
Country | Germany |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Hospital |
Article published date | 2025-10-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Hospital projects in Germany
- Boehringer Ingelheim’s New Tablet Production Facility, Ingelheim
- Hameln Pharma Sterile Facility
- Takeda Pharmaceutical Manufacturing Facility, Oranienburg
- Merck Serono Biopharmaceutical R&D Facility Expansion, Darmstadt
- Evonik’s Pharmaceutical Lipids Manufacturing Facility, Hanau, Germany
- Wacker Chemie Biologics Production Facility
- Boehringer Ingelheim Biologicals Development Centre (BDC), Biberach, Germany
- Haupt Pharma, New Packaging Line
